Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTP-choline-phosphate cytidylyltransferase (CCT) is a key regulatory enzyme in phosphatidylcholine (PC) biosynthesis, catalyzing the rate-limiting step in the CDP-choline pathway. It exists as two main isoforms, alpha (PCYT1A) and beta (PCYT1B), with distinct localization and regulation. CCT activity is regulated by membrane binding, phosphorylation, and lipid activators. Dysregulation is linked to developmental disorders, liver steatosis, and dyslipidemia. Inhibitors like CT-2584 have shown anti-tumor effects.
Inhibition of CTP-choline-phosphate cytidylyltransferase activity, leading to altered cellular lipid profiles and disruption of membrane integrity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTP-choline-phosphate cytidylyltransferase (CCT).